Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2017-06-08 Transaction in Own Shar…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Transaction in Own Shares Classification · 99% confidence The document text explicitly announces that Ipsen 'initiates share buy-back program' and details the appointment of a bank to purchase shares to cover a performance share allocation plan. This action falls directly under the category of the company transacting in its own shares (repurchase). This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). It is not a general financing update (CAP), nor is it a management change (MANG) or a dividend notice (DIV).
2017-06-08 English
Communicated under the obligation to provide permanent information / Other communications
AGM Information Classification · 98% confidence The document is titled "Combined Shareholders' Meeting of IPSEN S.A. held on 7 June 2017" and details the resolutions adopted, including dividend approval and board member appointments, which occurred during the meeting. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2017-06-07 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 100% confidence The document is titled "Assemblée Générale Mixte des Actionnaires de la société IPSEN S.A. du 7 juin 2017" (Mixed General Shareholders' Meeting of IPSEN S.A. of June 7, 2017). It explicitly states that all resolutions submitted to shareholder votes were adopted, details the dividend distribution approved, and announces the renewal and appointment of board members. These are the core activities and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2017-06-07 French
Share buybacks / Liquidity contracts Description of share buyback program
Transaction in Own Shares Classification · 98% confidence The document is titled "Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to the approval of the Combined Shareholders' Meeting to be held on 7 June 2017." It explicitly details the objectives, characteristics, maximum amount, and duration of a proposed share repurchase program, which is a form of capital management or transaction in own shares. Since the document describes the plan for the company to buy back its own shares, it directly relates to the definition of 'Transaction in Own Shares' (POS). While it relates to capital structure, the specific focus on repurchases makes POS a better fit than CAP (Capital/Financing Update). It is a detailed description, not just a brief announcement of a publication, so RPA/RNS is less appropriate.
2017-06-01 English
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 98% confidence The document is a 'Descriptif du cadre réglementaire du programme de rachat d'actions' (Description of the regulatory framework for the share buyback program) submitted for approval at the Annual General Meeting (AGM) on June 7, 2017. It details the objectives, modalities, maximum price, and duration of a proposed share repurchase program. This directly relates to the company's capital structure management and transactions involving its own shares. The filing type 'Transaction in Own Shares' (POS) is the most specific fit for a document detailing a share repurchase program, even though it is presented in the context of an upcoming shareholder vote (which might suggest DEF 14A or AGM-R). Since the core subject is the mechanics and authorization of buying back shares, POS is the primary classification. The document is not a simple announcement of a completed transaction but a proposal/framework for a future transaction.
2017-06-01 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 95% confidence The document is a press release dated June 1, 2017, announcing that Ipsen will present new data on several of its oncology products (lanreotide, cabozantinib, irinotecan liposome injection, and investigational compounds) at the American Society of Clinical Oncology (ASCO) 2017 conference. It details the specific abstracts, poster sessions, and presentation times for these data. This type of announcement, detailing upcoming scientific presentations and data releases, is characteristic of an Investor Presentation (IP) or a general corporate update related to R&D progress, rather than a formal regulatory filing (like 10-K or IR) or a simple earnings release (ER). Since it is a detailed presentation of scientific findings intended for investors and the medical community, 'Investor Presentation' (IP) is the most fitting category, even though it is announcing presentations rather than being the presentation itself. However, given the options, it functions as a detailed update on product pipeline progress, which aligns closely with the intent of an Investor Presentation (IP) or a comprehensive corporate update. It is not a short announcement of a report (RPA/RNS), as it contains substantial detail about the data being presented. It is not an Earnings Release (ER) as it focuses on clinical data, not financial performance highlights. Therefore, IP is the best fit.
2017-06-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.